(PHAS) – StreetInsider.com Reports
-
PhaseBio Pharmaceuticals Inc. (PHAS) Announces CFO Resignation
-
Cowen Downgrades PhaseBio Pharmaceuticals Inc. (PHAS) to Market Perform
-
PhaseBio Pharmaceuticals Inc. (PHAS) Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.88%
-
UPDATE: Stifel Downgrades PhaseBio Pharmaceuticals Inc. (PHAS) to Hold
-
Needham & Company Downgrades PhaseBio Pharmaceuticals Inc. (PHAS) to Hold
-
William Blair Downgrades PhaseBio Pharmaceuticals Inc. (PHAS) to Market Perform
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Successful Pre-BLA Meeting with the FDA for Bentracimab
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Positive Results from Phase 2b Trial for Bentracimab
-
PhaseBio Pharmaceuticals (PHAS) PT Slashed to $10 by Needham, Buy Reiterated, Sees bentracimab's Potential Undervalued Despite Capital Overhang
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Q4 Results, Provides Recent Business Highlights
-
PhaseBio Pharmaceuticals Inc. (PHAS) Provides Update on Bentracimab Manufacturing
-
PhaseBio Pharmaceuticals Inc. (PHAS) to Present Bentracimab Phase 2b Trial Data
-
PhaseBio's (PHAS) Halt of PB1046 is a Necessary Step to Focus on Bentracimab, Reiterate Buy - Needham
-
PhaseBio Pharmaceuticals Inc. (PHAS) is voluntarily ending Phase 2b trial of pemziviptadil in PAH due to COVID-19 impacts on manufacturing
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab
-
PhaseBio (PHAS) Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing
-
PhaseBio Pharmaceuticals Inc. (PHAS) Announces Topline Results From Phase 2b Trial for Bentracimab
-
Stifel Starts PhaseBio Pharmaceuticals Inc. (PHAS) at Buy
-
PhaseBio Pharmaceuticals Inc. (PHAS) Appoints William D. Humphries to its Board; Justin Klein Steps Down
-
PhaseBio Pharmaceuticals (PHAS) and SFJ Pharmaceuticals Announce Approval of IND Application in China for Bentracimab
-
PhaseBio Pharmaceuticals Inc. (PHAS) NDR Takeaways - Stifel
-
PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $15 at Needham & Company, Keeps 'Buy'
-
PhaseBio (PHAS) Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
-
PhaseBio Pharmaceuticals Inc. (PHAS) Real-World Bleeding and Surgery Data Featured at ACC
-
PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $16 at Needham & Company
-
PhaseBio Pharmaceuticals Inc. (PHAS) Prices 16M Share Common Offering at $3.50/Sh
-
PhaseBio Pharmaceuticals Inc. (PHAS) to Offer Common Stock
-
PhaseBio Pharmaceuticals Inc. (PHAS) PT Raised to 'Street High' $19 at Needham & Company
-
PhaseBio Pharmaceuticals Inc. (PHAS) Halted on LUDP, Up 12%
-
PhaseBio Pharmaceuticals Inc. (PHAS) and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab
-
PhaseBio Pharmaceuticals Inc. (PHAS) has elected to discontinue VANGARD clinical trial
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports First Patient Doses in Canada as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
-
Pre-Open Movers 07/17: (APDN) (OCN) (HMHC) Higher; (NIO) (NFLX) (ROKU) Lower (more...)
-
After-Hours Stock Movers 07/16: (FRGI) (PHAS) (PPG) Higher; (JBHT) (NFLX) (ROKU) Lower (more...)
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports First Patient Dosing in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients
-
Stifel Assumes PhaseBio Pharmaceuticals Inc. (PHAS) at Buy
-
Pre-Open Stock Movers 05/28: (PHAS) (TGI) (DLTR) (TOL) (ALXN) (HTZ) (TWTR) (More...)
-
After-Hours Stock Movers 05/27: (PHAS) (SMTC) (TOL) Higher; (IOVA) (ARNA) (PLT) Lower (more...)
-
PhaseBio (PHAS) Launches Clinical Trial to Evaluate PB1046 as Treatment for Hospitalized COVID-19 Patients
-
PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $11 at Citi
-
PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $14 at Stifel, Following Earnings
-
PhaseBio Pharmaceuticals Inc. (PHAS) Announces Alex C. Sapir to Board
-
PhaseBio Pharmaceuticals (PHAS) Announces European Regulatory Update for PB2452
-
PhaseBio Pharmaceuticals Inc. (PHAS) Presents Case Study Highlighting PB1046 Hemodynamic Data at PVRI 2020 Meetings
-
PhaseBio Pharmaceuticals (PHAS) Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor
-
PhaseBio (PHAS) Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals for PB2452
-
PhaseBio Pharmaceuticals Inc. (PHAS) Halted, News Pending
-
Citi Reiterates Buy Rating on PhaseBio (PHAS); Most Undervalued in Coverage
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports First Patient Dosed in Phase 2b Clinical Trial of PB2452
Back to PHAS Stock Lookup